Vanucizumab

Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.^[1][2]

Vanucizumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	angiopoietin 2
Clinical data
Other names	RG7221
ATC code	none
Identifiers
CAS Number	1448221-05-3
ChemSpider	none
UNII	B800Z06O8K
KEGG	D11244
Chemical and physical data
Formula	C6529H10033N1733O2038S46
Molar mass	146887.94 g·mol−1

Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.^[3]

This drug was developed by Genentech/Roche.^{[citation needed]}